Skip to main content

Think You Might Have AF? There's an App For That


WORCHESTER, Massachusetts — Innovative researchers have developed a smartphone-based application that allows patients to detect an irregular pulse caused by atrial fibrillation [1]. Two algorithms developed for the application that analyzed signals using an iPhone 4S successfully distinguished atrial fibrillation from sinus rhythm, report investigators.
"A number of patients who are referred to us have pretty symptomatic atrial fibrillation," said lead investigator Dr David McManus (University of Massachusetts Medical School, Worchester, MA). "So they are highly motivated to keep track of their episodes. We traditionally order Holter monitors and event monitors to capture the coming-and-going episodes of atrial fibrillation. I thought there was a potential role to leverage the fact that everybody has a smartphone and to use that as a means to do a sort of physiological assay of the patient."
The results of the study are published online December 7, 2012 in Heart Rhythm.
App Uses Camera and Flash to Measure Chaos in Pulse
To heart wire , McManus explained that patients often wear Holter and event monitors for up to 30 days in order to capture an atrial-fibrillation event, but some of the paroxysmal events are so infrequent that physicians might not even bother with the monitors. A phone-based rhythm-assessment tool would have positive implications for accessibility, allowing patients to record their pulse while the event is occurring to determine whether they are in fact having an episode of atrial fibrillation.
The application works using the smartphone camera and the flash to illuminate the fingertip when it is placed on top of the camera surface. Not unlike a pulse oximeter, which uses infrared light, the flash lens works to illuminate the finger as the camera records in real time the changes in the color of the fingertip. The changes in color act as a surrogate for blood flow, and this is in turn processed by a computer program embedded within the smartphone. Two algorithms--the root mean square of successive RR differences and Shannon entropy--analyze the degree of "chaos," or the variability of the pulse waveform.
"For the purposes of this study, we had patients keep their fingertip on the camera for two minutes, but we have that down now where we've shown that even one minute is sufficient," said McManus. "So it's a quick biopsy of person's pulse that appears to be highly accurate compared with a 12-lead ECG, which is what we used in this study."
In the study, 76 adults with persistent atrial fibrillation scheduled to undergo elective cardioversion were included in the analysis. All subjects who had a preprocedure ECG placed their finger on an iPhone 4S camera for two minutes while the program ran. Following cardioversion, patients successfully converted to normal sinus rhythm again reapplied their finger to the smartphone as another recording was obtained. The algorithms had excellent sensitivity (0.962), specificity (0.975), and accuracy (0.968) for the discrimination of an irregular pulse during atrial fibrillation from sinus rhythm.
"This is really the first step, showing that when it is used in the hospital setting, where a coach was showing them how to put their finger on the phone, people could successfully use this phone to know if they were in or out of atrial fibrillation," said McManus.
Young and Old, Patients Want This
To heart wire , McManus said that patients are clamoring for such an application, particularly those with diagnosed and treated atrial fibrillation who want to be on top of how many episodes of the arrhythmia they are having. They don't want to travel to the hospital or the doctor's office every time they suspect they might be having an episode, however. "Patients want this at their fingertips," he said. "They want something quick, they wanted something that's accurate, and they want something that allows them to communicate effectively with their doctor, all the more reason for it to be a phone-based program."
The application allows users to send the results directly to their physician via email and also provides summaries of atrial-fibrillation burden over selected time periods, a useful feature for physicians to determine whether another antiarrhythmic agent might be needed. Future issues remain, however, regarding how the application will fit into traditional testing, the approval process, who pays for it, and how it will get billed. While those market-based issues remain to be worked out, McManus believes the application fills an unmet need.
"I have to say that I have done a lot of clinical studies, but I had absolutely no problem recruiting patients for this one. Universally, they all said this is really cool."
 

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more